Classic and Nonclassic Renin-Angiotensin Systems in the Critically Ill

Laurent Bitker, MD, MSc^{a,*},

Louise M. Burrell, MBChB, MRCP, MD, FRACP^b

KEYWORDS

• Acute kidney injury • Acute respiratory distress syndrome • Angiotensin
• Angiotensin-converting enzyme • Sepsis • Inflammation • Septic shock • Renin

KEY POINTS

- Activation of the endocrine renin-angiotensin system (RAS) cascade induces immediate metabolic, hemodynamic, and renal responses, in response to changes in blood pressure and homeostasis.
- Renin and angiotensin II are upregulated in the setting of sepsis and septic shock. Higher renin and angiotensin II and lower circulating angiotensin-converting enzyme levels are associated with worse survival.
- Classic and nonclassic RASs modulate the inflammatory and immune responses. The angiotensin II axis stimulates a proinflammatory beneficial antibacterial response.
- In patients with vasoplegic shock, the infusion of exogenous angiotensin II lowers vasopressor requirements, and improves renal-related outcomes.
- Experimental evidence supports the direct role of classic RAS in the pathophysiology of acute respiratory distress syndrome, whereas clinical data suggest a lung protective effect of angiotensin-converting enzyme 2 administration.

INTRODUCTION

The renin-angiotensin systems (RASs) regulate blood pressure, kidney function, and salt and water homeostasis. Modulation of RAS is central in the intensive care unit spectrum of diseases (eg, hemodynamic failure) and is associated with patient outcomes.^{1–7} The RASs are enzymatic cascades implicating sequential peptide

Disclosure Statement: The authors declare that they have no conflicts of interest.

^a Department of Intensive Care, ICU Research Office, Austin Hospital, 145 Studley Road, Heidelberg, Victoria 3084, Australia; ^b Department of Medicine, University of Melbourne, Austin Health, Austin Hospital, 145 Studley Road, Heidelberg, Victoria 3084, Australia

* Corresponding author.

E-mail address: laurent.bitker@austin.org.au

Crit Care Clin 35 (2019) 213–227

<https://doi.org/10.1016/j.ccc.2018.11.002>

0749-0704/19/© 2018 Elsevier Inc. All rights reserved.

criticalcare.theclinics.com

cleavage, leading to angiotensin generation by angiotensin-converting enzymes (ACEs).⁸ RAS also modulates inflammation and immune responses.^{8,9}

The angiotensin (Ang) (1–7)/ACE2 cascade is known as the nonclassic RAS, which acts as an endogenous counterregulatory arm to the angiotensin II (Ang II)/ACE axis.¹⁰ Both classic and nonclassic RAS have been identified at the tissue level, with paracrine effects dissociated from those of the circulating system.¹¹

Better understanding of RAS physiology has led to the development of high-potential therapies, of interest to the intensivist. Administration of exogenous Ang II in vasoplegic shock alleviated vasopressor requirements, and was associated with improved survival in patients with severe acute kidney injury (AKI).^{2,7} On the other hand, exogenous infusion of recombinant human ACE2 has demonstrated exciting lung protective properties in the context of the acute respiratory distress syndrome (ARDS).³

The scope of this review was to describe the classic and nonclassic RASs, and their physiologic effects, with an emphasis on their respective pathogenic and/or therapeutic roles in the context of critical illness.

THE CIRCULATING CLASSIC RENIN-ANGIOTENSIN SYSTEM

Two enzymatic cascades lead to the generation of the main endocrine agents of the classic and nonclassic RASs (see Fig. 2). Both arms exist as an endocrine (circulating) and a paracrine (tissue-based) system, with paracrine and autocrine effects independent of the systemic systems.^{11,12} The organ localizations of the RASs are presented in Fig. 1.

Peptides

Angiotensinogen is a glycosylated protein, produced by the hepatic lobules.¹³ Plasma levels are stable, and in excess when compared with circulating renin concentrations. Local generation of angiotensinogen also exists in the renal epithelium, brain, heart, adrenal, endothelial, and intestinal tissue.^{11,12} Ang I is a biologically inactive decapeptide generated by the proteolysis of angiotensinogen by renin.⁹

Ang II is the pivotal peptide of the classic RAS. This octapeptide is the product of the cleavage of Ang I by ACE, but may also be generated under the action of other enzymes.⁹ Plasma Ang II is rapidly degraded into Ang III, IV, or Ang (1–7), under the action of various enzymes (Fig. 2).

Ang III is the product of the cleavage of Ang II by aminopeptidase A, or by the cleavage of Ang (1–9) under the action of ACE.⁹ Like Ang II, Ang III is a potent vasopressor, a thirst and salt appetite stimulant, and an activator of aldosterone secretion.¹⁴ Ang IV mainly modulates cerebral blood flow and cognition, increases renal blood flow (RBF), and decreases water and sodium reabsorption in the renal epithelium.^{15,16}

Enzymes

Renin is an aspartyl-protease released by the juxta-glomerular apparatus, and is the key rate-limiting factor of Ang II generation.⁸ Its secretion is regulated by renal perfusion, sodium-chloride balance, sympathetic nervous tone, and Ang II (Box 1).^{17–19} Renin has also been identified in the proximal tubule and distal nephron, the brain, and in some immune system circulating elements.^{20,21}

ACE is a dicarboxypeptidase metalloenzyme that generates Ang II, via a zinc-dependent shedding of a C-terminal dipeptide from Ang I. ACE also generates Ang (1–7) from Ang (1–9), and inactivates bradykinin, a natriuretic and vasodilator

Fig. 1. Localization of RASs. Presented here are the organs or tissues in which at least 1 component of classic and/or nonclassic systems have been identified and are considered as being locally generated and/or secreted.

peptide.²² The protein is a transmembrane ecto-enzyme found mainly in the pulmonary endothelium, where most of the Ang II is generated, but also in the brain, heart, and renal endothelium, and immune system cellular components.^{23–25}

Receptors

Ang II receptors are G protein-coupled transmembrane proteins with 7 membrane-spanning domains.²⁶

Angiotensin type 1 receptor (AT₁R) represents the principal transducer of Ang II into its main physiologic responses.²⁶ AT₁R is found in the endothelium (smooth muscular cells), kidneys (glomeruli and proximal tubule), adrenal glands, heart, lymphocytes, and granulocytes.^{27–29} Ang II-AT₁R binding induces the activation of multiple intracellular secondary messenger cascade, including intracellular Ca²⁺, nuclear factor (NF) κ B, phospholipase C and Janus kinase families.²⁷

Angiotensin type 2 receptor (AT₂R) presents a 34% homology with AT₁R and is similarly structured.²⁶ It is found in the endothelium, heart, brain, kidneys and adrenal glands. AT₂R main actions antagonize those of AT₁R. *Angiotensin type 4 receptor* (AT₄R) is principally located in the brain, and to a lesser extent in the renal artery, and binds Ang IV.¹⁵

Fig. 2. RASs enzymatic cascades. AP-A, aminopeptidase A; AP-B, aminopeptidase B; AP-N, aminopeptidase N.

PHYSIOLOGY OF THE CIRCULATING CLASSIC RENIN-ANGIOTENSIN SYSTEM

The physiologic effects of classic RAS upregulation are summarized in [Fig. 3](#).

Renal Physiology

Regulation of renal blood flow and glomerular filtration rate

Ang II augments glomerular filtration rate (GFR) and RBF, by increasing the vasomotor tone of efferent renal arterioles, acting alongside with myogenic reflex activation and

Box 1	
Mechanisms leading to renin release by the juxta-glomerular apparatus	
Physiologic Trigger	Description
Renal perfusion pressure	Baroreceptors in the juxta-glomerular apparatus are sensitive to changes in renal perfusion pressure below 90 mm Hg. This effect is immediately transduced to the juxta-glomerular cells, due to their intimate contact with the <i>macula densa</i> , forming the juxta-glomerular apparatus. Evidence suggest that this effect is mainly due to chloride depletion.
Na+ and Cl- delivery to the macula densa	The sympathetic autonomous neural system, through a dense population of β_1 - noradrenergic nerves, directly stimulates renin release by the juxta-glomerular apparatus. These effects are dissociated from those induced by changes in renal perfusion pressure.
Adrenergic activation	Negative short-loop biofeedback by Ang II binding of AT ₁ R present in the juxta-glomerular cell membrane.
Angiotensin II: acute stimulus	This compensatory mechanism, named juxta-glomerular recruitment, increases the number of renin-secreting cells in upregulated Ang II environments.
Angiotensin II: chronic stimulus	
Abbreviations: Ang II, angiotensin II; AT ₁ R, angiotensin II type 1 receptor.

Fig. 3. Mirrorlike physiologic effects of the pivotal peptides of the classic and nonclassic RASs. BP, blood pressure; CNS, central nervous system. The question mark indicates the unknown/unexplored effect of Angiotensin (1-7), in regard to that observed with Angiotensin II upregulation.

tubulo-glomerular feedback.^{8,9,30} Its effects seem maximum when blood pressure is sufficiently low to stimulate renin release.³¹ However, overstimulation by Ang II may decrease GFR due to excessive vasoconstriction.

Sodium homeostasis and acid-base balance regulation

Local and circulating Ang II stimulate the AT₁R-dependent reabsorption of sodium, chloride, and bicarbonate and excretion of potassium and protons by the renal epithelia.⁹ It activates the apical Na⁺/H⁺ exchanger coupled with a basal Na⁺/HCO₃⁻ cotransporter in the proximal tubule and the ascending limb of the loop of Henle.³² Ang II also activates Na⁺/K⁺ ATPase anti-transporters (leading to increased kaliuresis) and pendrin, a Cl⁻/HCO₃⁻ anti-transporter involved in chloride reabsorption.³³ Finally, aldosterone augments the recruitment of Na⁺/K⁺ ATPase and epithelial sodium channel transporters in the distal tubules and collecting ducts.³⁰

Cardiovascular Physiology

Although the effects of Ang II on blood pressure are partly related to extracellular volume regulation, Ang II is a potent vasopressor agent, via an AT₁R-dependent influx of calcium into smooth muscular cells cytoplasm, but is downregulated by Ang II/AT₂R-dependent NO endothelial production and bradykinin generation^{34,35}; however, vasomotor modulation may vary between and within organs.³⁶ Suvannapura and Levens³⁷ observed splanchnic vasoconstriction at normal Ang II circulating levels, whereas none was observed on RBF. Finally, Ang II increases blood pressure by upregulating adrenergic stimulation and endothelin 1 (ET-1) transcription.^{38,39} Finally, Ang II increases cardiac output by inhibiting the vagal tone and upregulating ET-1.⁴⁰

Other Effects

Ang II (and Ang III) stimulates adrenal synthesis and release of aldosterone and of catecholamines, and induces adrenal hypertrophy.³⁹ In the brain, circulating and locally

produced Ang II stimulates thirst and salt-seeking behavior, vasopressin release by the posterior hypophysis, and acts as a central stimulant of sympathetic nervous tone.^{9,14,27,41,42}

THE NONCLASSIC RENIN-ANGIOTENSIN SYSTEM

Nonclassic Renin-Angiotensin System Angiotensins

Angiotensin (1–7) is a heptapeptide produced by the proteolysis of Ang II by ACE2 (see Fig. 2).¹⁰ Cleavage of Ang (1–9) by ACE also generates Ang (1–7). Ang (1–7) is found in the plasma, heart, renal, and brain tissues, and may be excreted in the urine. Ang (1–7) binds the Mas receptor, through which most of its known effects are mediated.⁴³ Angiotensin (1–9) is a nonapeptide generated by the ACE2-related breakdown of Ang I, acting as a competitor to ACE-related generation of Ang II.⁴⁴ It is a potent cardioprotective antifibrotic agent that binds the AT₂R.^{44,45}

Angiotensin-Converting Enzyme 2

ACE2 is the pivotal enzyme of the nonclassic RAS.¹⁰ ACE2 is transmembrane monooxypeptidase that converts Ang II into Ang (1–7) and Ang I into Ang (1–9). ACE2 was simultaneously discovered by 2 independent groups, using 2 complementary DNA libraries (heart and lymphoma).^{46,47} ACE2 is the receptor to the severe acute respiratory syndrome coronavirus, and has been identified in the kidneys, lungs, brain, heart, and testes.^{10,48,49} Through the generation of Ang (1–7), and the degradation of Ang II, the effect of ACE2 is tissue-protective. Due to structural differences in the binding sites of ACE and ACE2, ACE inhibitors do not inhibit the activity of ACE2.⁵⁰

The Mas Receptor

The *Mas receptor* is a G-protein-coupled transmembrane receptor with high affinity for Ang (1–7), and little affinity for Ang II.⁴³ The receptor is distributed along the intrarenal epithelium and vascular endothelium, in accordance with the renal and hemodynamic effects of Ang (1–7).⁵¹

Nonclassic Renin-Angiotensin System and the Cardiovascular System

Ang (1–7) induces systemic and local vasodilation, by upregulating NO production.⁵¹ Ang (1–7) and ACE2 have demonstrated cardioprotective anti-inflammatory features in an experimental model of myocardial infarction and heart failure (decreased reactive oxygen species [ROS] production and fibroblasts recruitment).^{52–57} However, these observations were contradicted by the observation of cardiac fibrosis after Ang (1–7) upregulation in experimental renal dysfunction, in relation to a compensatory increase in ACE.⁵⁸

Nonclassic Renin-Angiotensin System and Renal Function

In the kidneys, the activation of the Mas receptor by Ang (1–7) increases RBF and GFR, natriuresis, and diuresis.^{59,60} Ang (1–7) and ACE2 may also present renoprotective properties, although limited by the potential compensatory upregulation of Ang II.^{60–63} The role of ACE2 circulating levels in the context of chronic kidney disease remains controversial.^{64,65}

RENIN-ANGIOTENSIN SYSTEMS AND THE IMMUNE SYSTEM

Classic and nonclassic RAS modulate the innate and adaptive immune system responses, regulating inflammation, cell proliferation, fibrogenesis, and apoptosis (Box 2).^{56,57,60,66,67} The Ang II/ACE axis potentiates bacterial clearance, by

Box 2**Immunomodulatory mechanisms and consequences of classic and nonclassic renin-angiotensin systems**

Angiotensin II/ACE/AT₁R axis	Angiotensin (1–7)/ACE2/Mas axis
NFκB upregulation	NFκB downregulation
Increase in production of ROS	Downregulation of ROS production
Increase in secretion of proinflammatory cytokines	Lower proinflammatory cytokine levels
Collagen production	Antiproliferative effect
Macrophages/neutrophils recruitment	Decrease macrophage tissue recruitment
Activation of fibroblasts	Decrease fibroblast activation
Fibrosis, apoptosis	Tissue protection
<i>Abbreviations:</i> ACE2, angiotensin-converting enzyme2; AT ₁ R, angiotensin II type 1 receptor; NFκB, nuclear factor κB; ROS, reactive oxygen species.	

upregulating neutrophils and macrophages chemotaxis and activation, generation of ROS, and secretion of proinflammatory cytokines.^{28,68,69} Yet, lymphocytic AT₁R activation inhibits CD8⁺ T-cell activation.^{25,29} These phenomena modulate the NFκB cascade, a transcription factor involved in both the physiology and pathogenesis of septic shock and organ failure.^{70–72} These effects also may be directly mediated by ACE, as suggested by the effects of ACE inhibitors but not by AT₁R antagonists on immunomodulation.⁷³ In sheer contrast, activation of the Ang (1–7)/ACE2 axis inhibits ROS production, downregulates proinflammatory cytokine secretion, and has immunomodulatory tissue-protective features (see **Box 2**).^{60,62,66,74}

ANGIOTENSIN II IN VASODILATORY SHOCK AND SEPSIS

In the critical setting, the upregulation of the classic RAS is a physiologic and potentially life-saving response. Ang II and renin levels are increased in the context of sepsis and significantly associated with severity of disease.^{1,6,75} Serum ACE concentration in patients with pulmonary sepsis were lower than in healthy volunteers, with reduced levels associated with increased mortality.^{6,76} In line with our understanding of Ang II effects, recent data strongly suggest that exogenous Ang II infusion decreases vasopressor dose requirements in patients with vasodilatory shock, mirroring the physiologic effects of endogenous Ang II: increase in sympathetic tone, endogenous catecholamine and vasopressin release, and direct stimulation of vascular smooth muscle cells.²

During sepsis, Ang II upregulation may induce ROS generation and endothelial structural changes, both being pivotal physiologic responses to infection, yet also central in the pathogenesis of its most severe presentation, namely septic shock, where they become oxidative stress and endothelial dysfunction.¹ Historically, although meeting promising successes in animal models, ACE inhibition did not prove to attenuate the inflammatory response in healthy volunteers exposed to endotoxemia.^{77,78} Furthermore, large observational evidence was not supportive of classic RAS downregulation having protective effects against sepsis.⁷⁹ Conversely, Ang II improved phagocytosis and inhibited abscess formation during experimental murine peritonitis.⁸⁰ In the ATHOS-3 trial, the vast majority of patients had confirmed or suspected sepsis. Ang II infusion at the acute phase of vasodilatory shock of septic origin also may contribute to an unknown degree of inflammation enhancement and bacterial clearance.

ANGIOTENSIN-CONVERTING ENZYMES IN ACUTE RESPIRATORY DISTRESS SYNDROME

ACE levels were respectively increased in the broncho-alveolar lavage and decreased in the serum of patients with ARDS, whereas higher circulating levels of Ang I were associated with mortality.^{5,76,81} The epithelial and endothelial damage observed in the course of ARDS may create an imbalance favoring classic over nonclassic RAS pathways in the lungs.⁸² Although little is known about Ang II in human ARDS, upregulation of the Ang II/ACE cascade in experimental ARDS worsens perfusion/ventilation mismatch, increases secretion of proinflammatory intracellular cascades and agents, and local production of ROS, all directly implicated in the disease's pathogenesis.⁴ Classic RAS inhibition may limit the pulmonary inflammatory response and the extent of lung injury, but has been poorly evaluated in humans.^{77,83,84}

In contrast, growing evidence suggests the pivotal role of nonclassic RAS in lung protection in the face of acute injury. First, ACE2 was identified as being the receptor to the severe acute respiratory syndrome coronavirus, via the Spike protein. Inhibition of ACE2-coronavirus binding effectively inhibited virus replication and limited RAS-dependent acute lung injury.⁸⁵ Then, experimental models of ARDS modulating Ang (1–7) and ACE2 activities have demonstrated significant lung protection (Fig. 4).^{74,86,87} Ang (1–7) infusion in murine experimental ARDS decreased the proinflammatory response, improved lung injury scores and lung function, and decreased cellular infiltrate in piglets with acid aspiration.^{74,82} These beneficial effects are mediated by downregulation of the intracellular proinflammatory NFκB cascade and increased NO synthesis.⁵¹ A randomized controlled trial of recombinant human ACE2 in humans with ARDS showed it decreased Ang II levels and proinflammatory mediators, and augmented plasmatc surfactant protein D, with no hemodynamic side effects.^{3,88} The effects of recombinant human ACE2 (rhACE2) may be principally mediated by its competing effects with ACE in limiting the generation of Ang II, while potentiating Ang (1–7) activity. Those findings demonstrate that ACE2-related immunomodulation in the context of ARDS may improve pulmonary outcomes, in

Fig. 4. ACE2 controls acute lung failure. Lung elastance (A) after acute lung injury in wild-type (WT) and *Ace2* knockout (KO) mice induced by cecal ligation perforation (CLP). CLP-treated *Ace2* KO mice had significantly higher elastance than CLP-treated WT mice (^a $P < .01$). Wet-to-dry weight ratios of lungs (B) in CLP-treated *Ace2* KO mice after 4 hours of ventilation was significantly increased, compared with CLP-treated WT and sham. Histopathology (C) showed increased lung edema and inflammatory infiltrate in CLP-treated *Ace2* knockout mice, compared to CLP-treated WT and sham. ^b $P < .05$ between CLP-treated WT and *Ace2* KO mice. (From Imai Y, Kuba K, Rao S, et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. *Nature* 2005;436:114; with permission.)

congruence with what we know of the downregulating effect of nonclassic RAS on the inflammatory response. Larger randomized controlled trials are necessary to confirm the promising lung protective properties of rhACE2.

PLACE OF RENIN-ANGIOTENSIN SYSTEMS IN ACUTE KIDNEY INJURY

Evidence in AKI suggests a complex picture. In patients with suspected acute tubular necrosis, angiotensinogen and Ang II expression and urinary secretion are increased, and associated with the severity of pathology and AKI risk.^{89,90} However, whether the upregulation of the classic RAS is the cause or the consequence of AKI remains unknown and findings may be model-dependent. Ang II upregulation improves renal function, while not aggravating medullary hypoxia, in an experimental model of septic AKI, and attenuates intrarenal inflammation and apoptosis in murine ischemia/reperfusion-induced AKI.^{91,92} Interaction of local and systemic systems may also be of importance. Renal injury may depend on renal cell AT₁R activation, whereas a reno-protective phenotype is observed if lymphocytes AT₁R are activated.⁹³ The Ang II/Ang (1–7) balance may also play a role, as ACE2 knockout mice with ischemia/reperfusion-induced AKI showed worsening renal function.⁹⁴ From a clinical perspective, exogenous Ang II administration in patients with vasoplegic shock and severe AKI was associated with higher survival and renal replacement therapy weaning rates.⁷ The role of Ang II on renal recovery after AKI, well supported by experimental data, will require further evaluation in the critical setting.

INTEGRATION OF RENIN-ANGIOTENSIN SYSTEM PHYSIOLOGY IN CRITICAL ILLNESS

Description of the physiology of the classic and nonclassic RAS has direct implications in the setting of critical illness. On the one hand, increased Ang II activity is a life-saving response to hypotension and infection, with proven effects on cardiovascular physiology and renal outcomes in the context of vasoplegic shock.² It also implies that Ang II enhancement of hemodynamic management at the acute phase of septic shock may improve organ failure, including renal failure. Also, Ang II in the acute context may boost the proinflammatory response, with subsequent enhanced bacterial clearance, opposite to the deleterious effects of inflammation in the chronic setting. On the other hand, ACE2 enhancement decreases lung inflammation and improves lung hemodynamics and function in the setting of ARDS.³ The control of pulmonary damage by the nonclassic RAS demonstrates the central role of

Fig. 5. The paradigm of classic and nonclassic RAS roles in critical illness.

immunomodulation in this potentially lethal inflammation-mediated disease. Those 2 pivotal trials convey highly encouraging changes in the treatment strategies of septic shock and ARDS. Yet, their individualization at the bedside is far from being achieved, as both targeted conditions may be simultaneously present in a given individual (Fig. 5). Better understanding of how local and systemic systems interact may help target which should be favored.

SUMMARY

Our knowledge of the RASs is growing exponentially and exposing their complexity. The RAS is more than an endocrine system, and exists in most organs, with local physiologic and biological effects dissociated from the classic circulating RAS. In the context of critical illness, the regulation of the classic/nonclassic RAS balance plays a unique role in the response to vasodilatory shock and ARDS. Rapidly evolving clinical data suggest that Ang II may save lives in vasodilatory shock and accelerate renal recovery in patients with severe AKI in this setting. Conversely, ACE2 may prove an important new protective therapy in ARDS. A new chapter of the RAS, now dealing with critical illness, is being written and opens the door to a new concept in the manipulation of this ubiquitous system: inhibition in the chronic setting but activation in the acute setting.

REFERENCES

1. Doerschug KC, Delsing AS, Schmidt GA, et al. Renin-angiotensin system activation correlates with microvascular dysfunction in a prospective cohort study of clinical sepsis. *Crit Care* 2010;14(1):R24.
2. Khanna A, English SW, Wang XS, et al. Angiotensin II for the treatment of vasodilatory shock. *N Engl J Med* 2017;377(5):419–30.
3. Khan A, Benthin C, Zeno B, et al. A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome. *Crit Care* 2017;21(1):234.
4. Cruces P, Diaz F, Puga A, et al. Angiotensin-converting enzyme insertion/deletion polymorphism is associated with severe hypoxemia in pediatric ARDS. *Intensive Care Med* 2012;38(1):113–9.
5. Annoni F, Orbegozo Cortés D, Irazabal M, et al. Angiotensin converting enzymes in patients with acute respiratory distress syndrome. *Intensive Care Med Exp* 2015;3(1):A91.
6. Zhang W, Chen X, Huang L, et al. Severe sepsis: low expression of the renin-angiotensin system is associated with poor prognosis. *Exp Ther Med* 2014;7(5):1342–8.
7. Tumlin JA, Murugan R, Deane AM, et al. Outcomes in patients with vasodilatory shock and renal replacement therapy treated with intravenous angiotensin II. *Crit Care Med* 2018;46(6):949–57.
8. Sparks MA, Crowley SD, Gurley SB, et al. Classical renin-angiotensin system in kidney physiology. *Compr Physiol* 2014;4(3):1201–28.
9. Ballermann BJ, Onuigbo MA. Angiotensins. *Compr Physiol* 2011;(Supplement 22):104–55.
10. Chappell MC. Nonclassical renin-angiotensin system and renal function. *Compr Physiol* 2012;2(4):2733–52.
11. Paul M, Poyan Mehr A, Kreutz R. Physiology of local renin-angiotensin systems. *Physiol Rev* 2006;86(3):747–803.

12. Yang T, Xu C. Physiology and pathophysiology of the intrarenal renin-angiotensin system: an update. *J Am Soc Nephrol* 2017;28(4):1040–9.
13. Matsusaka T, Niimura F, Shimizu A, et al. Liver angiotensinogen is the primary source of renal angiotensin II. *J Am Soc Nephrol* 2012;23(7):1181–9.
14. Wright JW, Bechtholt AJ, Chambers SL, et al. Angiotensin III and IV activation of the brain AT1 receptor subtype in cardiovascular function. *Peptides* 1996;17(8):1365–71.
15. Kramar EA, Harding JW, Wright JW. Angiotensin II- and IV-induced changes in cerebral blood flow. Roles of AT1, AT2, and AT4 receptor subtypes. *Regul Pept* 1997;68(2):131–8.
16. Handa RK, Krebs LT, Harding JW, et al. Angiotensin IV AT4-receptor system in the rat kidney. *Am J Physiol* 1998;274(2 Pt 2):F290–9.
17. Bock HA, Hermle M, Brunner FP, et al. Pressure dependent modulation of renin release in isolated perfused glomeruli. *Kidney Int* 1992;41(2):275–80.
18. Thureau K, Schnermann J, Nagel W, et al. Composition of tubular fluid in the macula densa segment as a factor regulating the function of the juxtaglomerular apparatus. *Circ Res* 1967;21(1 Suppl 2):79–90.
19. Kirchheim HR, Ehmke H, Hackenthal E, et al. Autoregulation of renal blood flow, glomerular filtration rate and renin release in conscious dogs. *Pflügers Arch* 1987;410(4–5):441–9.
20. Rohrwasser A, Morgan T, Dillon HF, et al. Elements of a paracrine tubular renin-angiotensin system along the entire nephron. *Hypertension* 1999;34(6):1265–74.
21. Mackins CJ, Kano S, Seyedi N, et al. Cardiac mast cell-derived renin promotes local angiotensin formation, norepinephrine release, and arrhythmias in ischemia/reperfusion. *J Clin Invest* 2006;116(4):1063–70.
22. Hornig B, Kohler C, Drexler H. Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans. *Circulation* 1997;95(5):1115–8.
23. Alhenc-Gelas F, Corvol P. Molecular and physiological aspects of angiotensin I converting enzyme. *Compr Physiol* 2011;(Supplement 22):81–103.
24. Bruneval P, Hinglais N, Alhenc-Gelas F, et al. Angiotensin I converting enzyme in human intestine and kidney. Ultrastructural immunohistochemical localization. *Histochemistry* 1986;85(1):73–80.
25. Coppo M, Bandinelli M, Chiostrì M, et al. Persistent and selective upregulation of renin-angiotensin system in circulating T lymphocytes in unstable angina. *J Renin Angiotensin Aldosterone Syst* 2017;18(1). 1470320317698849.
26. Guthrie GP Jr. Angiotensin receptors: physiology and pharmacology. *Clin Cardiol* 1995;18(6 Suppl 3):III 29–34.
27. Allen AM, Zhuo J, Mendelsohn FA. Localization and function of angiotensin AT1 receptors. *Am J Hypertens* 2000;13(1 Pt 2):31S–8S.
28. Hernandez-Presa M, Bustos C, Ortego M, et al. Angiotensin-converting enzyme inhibition prevents arterial nuclear factor-kappa B activation, monocyte chemoattractant protein-1 expression, and macrophage infiltration in a rabbit model of early accelerated atherosclerosis. *Circulation* 1997;95(6):1532–41.
29. Zhang JD, Patel MB, Song YS, et al. A novel role for type 1 angiotensin receptors on T lymphocytes to limit target organ damage in hypertension. *Circ Res* 2012;110(12):1604–17.
30. Taal MWB, Barry M. 1937–; Rector. In: Floyd C, editor. *Brenner & Rector's the kidney*. 9th edition. Philadelphia: Elsevier/Saunders; 2012.
31. Hall JE, Guyton AC, Cowley AW Jr. Dissociation of renal blood flow and filtration rate autoregulation by renin depletion. *Am J Physiol* 1977;232(3):F215–21.

32. Geibel J, Giebisch G, Boron WF. Angiotensin II stimulates both Na⁺-H⁺ exchange and Na⁺/HCO₃⁻ cotransport in the rabbit proximal tubule. *Proc Natl Acad Sci U S A* 1990;87(20):7917–20.
33. Wall SM, Lazo-Fernandez Y. The role of pendrin in renal physiology. *Annu Rev Physiol* 2015;77:363–78.
34. Hall JE, Guyton AC, Smith MJ Jr, et al. Blood pressure and renal function during chronic changes in sodium intake: role of angiotensin. *Am J Physiol* 1980;239(3):F271–80.
35. Heinemann A, Wachter CH, Holzer P, et al. Nitric oxide-dependent and -independent vascular hyporeactivity in mesenteric arteries of portal hypertensive rats. *Br J Pharmacol* 1997;121(5):1031–7.
36. Myers BD, Deen WM, Brenner BM. Effects of norepinephrine and angiotensin II on the determinants of glomerular ultrafiltration and proximal tubule fluid reabsorption in the rat. *Circ Res* 1975;37(1):101–10.
37. Suvannapura A, Levens NR. Local control of mesenteric blood flow by the renin-angiotensin system. *Am J Physiol* 1988;255(3 Pt 1):G267–74.
38. Rossi GP, Sacchetto A, Cesari M, et al. Interactions between endothelin-1 and the renin-angiotensin-aldosterone system. *Cardiovasc Res* 1999;43(2):300–7.
39. Peach MJ. Adrenal medullary stimulation induced by angiotensin I, angiotensin II, and analogues. *Circ Res* 1971;28(5 Suppl 2):107–17.
40. Cingolani HE, Villa-Abrille MC, Cornelli M, et al. The positive inotropic effect of angiotensin II: role of endothelin-1 and reactive oxygen species. *Hypertension* 2006;47(4):727–34.
41. Coble JP, Grobe JL, Johnson AK, et al. Mechanisms of brain renin angiotensin system-induced drinking and blood pressure: importance of the subfornical organ. *Am J Physiol Regul Integr Comp Physiol* 2015;308(4):R238–49.
42. Dendorfer A, Thornagel A, Raasch W, et al. Angiotensin II induces catecholamine release by direct ganglionic excitation. *Hypertension* 2002;40(3):348–54.
43. Santos RA, Simoes e Silva AC, Maric C, et al. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. *Proc Natl Acad Sci U S A* 2003;100(14):8258–63.
44. Flores-Munoz M, Smith NJ, Haggerty C, et al. Angiotensin1-9 antagonises pro-hypertrophic signalling in cardiomyocytes via the angiotensin type 2 receptor. *J Physiol* 2011;589(Pt 4):939–51.
45. Fattah C, Nather K, McCarroll CS, et al. Gene therapy with angiotensin-(1-9) preserves left ventricular systolic function after myocardial infarction. *J Am Coll Cardiol* 2016;68(24):2652–66.
46. Donoghue M, Hsieh F, Baronas E, et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. *Circ Res* 2000;87(5):E1–9.
47. Tipnis SR, Hooper NM, Hyde R, et al. A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. *J Biol Chem* 2000;275(43):33238–43.
48. Chappell MC. Emerging evidence for a functional angiotensin-converting enzyme 2-angiotensin-(1-7)-MAS receptor axis: more than regulation of blood pressure? *Hypertension* 2007;50(4):596–9.
49. Wiener RS, Cao YX, Hinds A, et al. Angiotensin converting enzyme 2 is primarily epithelial and is developmentally regulated in the mouse lung. *J Cell Biochem* 2007;101(5):1278–91.

50. Towler P, Staker B, Prasad SG, et al. ACE2 X-ray structures reveal a large hinge-bending motion important for inhibitor binding and catalysis. *J Biol Chem* 2004; 279(17):17996–8007.
51. Gwathmey TM, Westwood BM, Pirro NT, et al. Nuclear angiotensin-(1-7) receptor is functionally coupled to the formation of nitric oxide. *Am J Physiol Renal Physiol* 2010;299(5):F983–90.
52. Qi Y, Shenoy V, Wong F, et al. Lentivirus-mediated overexpression of angiotensin-(1-7) attenuated ischaemia-induced cardiac pathophysiology. *Exp Physiol* 2011; 96(9):863–74.
53. Grobe JL, Der Sarkissian S, Stewart JM, et al. ACE2 overexpression inhibits hypoxia-induced collagen production by cardiac fibroblasts. *Clin Sci (Lond)* 2007;113(8):357–64.
54. Burrell LM, Risvanis J, Kubota E, et al. Myocardial infarction increases ACE2 expression in rat and humans. *Eur Heart J* 2005;26(4):369–75 [discussion: 322–64].
55. Trask AJ, Groban L, Westwood BM, et al. Inhibition of angiotensin-converting enzyme 2 exacerbates cardiac hypertrophy and fibrosis in Ren-2 hypertensive rats. *Am J Hypertens* 2010;23(6):687–93.
56. Tallant EA, Ferrario CM, Gallagher PE. Angiotensin-(1-7) inhibits growth of cardiac myocytes through activation of the mas receptor. *Am J Physiol Heart Circ Physiol* 2005;289(4):H1560–6.
57. Patel VB, Bodiga S, Fan D, et al. Cardioprotective effects mediated by angiotensin II type 1 receptor blockade and enhancing angiotensin 1-7 in experimental heart failure in angiotensin-converting enzyme 2-null mice. *Hypertension* 2012; 59(6):1195–203.
58. Velkoska E, Dean RG, Griggs K, et al. Angiotensin-(1-7) infusion is associated with increased blood pressure and adverse cardiac remodelling in rats with subtotal nephrectomy. *Clin Sci (Lond)* 2011;120(8):335–45.
59. Heller J, Kramer HJ, Maly J, et al. Effect of intrarenal infusion of angiotensin-(1-7) in the dog. *Kidney Blood Press Res* 2000;23(2):89–94.
60. Pinheiro SV, Ferreira AJ, Kitten GT, et al. Genetic deletion of the angiotensin-(1-7) receptor Mas leads to glomerular hyperfiltration and microalbuminuria. *Kidney Int* 2009;75(11):1184–93.
61. Zhang J, Noble NA, Border WA, et al. Infusion of angiotensin-(1-7) reduces glomerulosclerosis through counteracting angiotensin II in experimental glomerulonephritis. *Am J Physiol Renal Physiol* 2010;298(3):F579–88.
62. Jin HY, Chen LJ, Zhang ZZ, et al. Deletion of angiotensin-converting enzyme 2 exacerbates renal inflammation and injury in apolipoprotein E-deficient mice through modulation of the nephrin and TNF- α -TNFRSF1A signaling. *J Transl Med* 2015;13:255.
63. Oudit GY, Liu GC, Zhong J, et al. Human recombinant ACE2 reduces the progression of diabetic nephropathy. *Diabetes* 2010;59(2):529–38.
64. Lely AT, Hamming I, van Goor H, et al. Renal ACE2 expression in human kidney disease. *J Pathol* 2004;204(5):587–93.
65. Reich HN, Oudit GY, Penninger JM, et al. Decreased glomerular and tubular expression of ACE2 in patients with type 2 diabetes and kidney disease. *Kidney Int* 2008;74(12):1610–6.
66. Bernstein KE, Khan Z, Giani JF, et al. Angiotensin-converting enzyme in innate and adaptive immunity. *Nat Rev Nephrol* 2018;14(5):325–36.
67. Sachse A, Wolf G. Angiotensin II-induced reactive oxygen species and the kidney. *J Am Soc Nephrol* 2007;18(9):2439–46.

68. Khan Z, Shen XZ, Bernstein EA, et al. Angiotensin-converting enzyme enhances the oxidative response and bactericidal activity of neutrophils. *Blood* 2017; 130(3):328–39.
69. Okwan-Duodu D, Datta V, Shen XZ, et al. Angiotensin-converting enzyme overexpression in mouse myelomonocytic cells augments resistance to *Listeria* and methicillin-resistant *Staphylococcus aureus*. *J Biol Chem* 2010;285(50): 39051–60.
70. Meng Y, Chen C, Liu Y, et al. Angiotensin II regulates dendritic cells through activation of NF-kappaB/p65, ERK1/2 and STAT1 pathways. *Cell Physiol Biochem* 2017;42(4):1550–8.
71. Abraham E. Nuclear factor-kappaB and its role in sepsis-associated organ failure. *J Infect Dis* 2003;187(Suppl 2):S364–9.
72. Ozawa Y, Kobori H. Crucial role of Rho-nuclear factor-kappaB axis in angiotensin II-induced renal injury. *Am J Physiol Renal Physiol* 2007;293(1):F100–9.
73. Shen XZ, Li P, Weiss D, et al. Mice with enhanced macrophage angiotensin-converting enzyme are resistant to melanoma. *Am J Pathol* 2007;170(6):2122–34.
74. Zambelli V, Bellani G, Borsa R, et al. Angiotensin-(1-7) improves oxygenation, while reducing cellular infiltrate and fibrosis in experimental acute respiratory distress syndrome. *Intensive Care Med Exp* 2015;3(1):44.
75. Hilgenfeldt U, Kienapfel G, Kellermann W, et al. Renin-angiotensin system in sepsis. *Clin Exp Hypertens A* 1987;9(8–9):1493–504.
76. Casey L, Krieger B, Kohler J, et al. Decreased serum angiotensin converting enzyme in adult respiratory distress syndrome associated with sepsis: a preliminary report. *Crit Care Med* 1981;9(9):651–4.
77. Shen L, Mo H, Cai L, et al. Losartan prevents sepsis-induced acute lung injury and decreases activation of nuclear factor kappaB and mitogen-activated protein kinases. *Shock* 2009;31(5):500–6.
78. Graninger M, Marsik C, Dukic T, et al. Enalapril does not alter adhesion molecule levels in human endotoxemia. *Shock* 2003;19(5):448–51.
79. Dial S, Nessim SJ, Kezouh A, et al. Antihypertensive agents acting on the renin-angiotensin system and the risk of sepsis. *Br J Clin Pharmacol* 2014;78(5): 1151–8.
80. Rodgers K, Xiong S, Espinoza T, et al. Angiotensin II increases host resistance to peritonitis. *Clin Diagn Lab Immunol* 2000;7(4):635–40.
81. Reddy LM, Baydur L, Liebler JM, et al. The role of renin-angiotensin peptides in the pathogenesis of acute respiratory distress syndrome. *Am J Respir Crit Care Med* 2017;195:A4773.
82. Wosten-van Asperen RM, Lutter R, Specht PA, et al. Acute respiratory distress syndrome leads to reduced ratio of ACE/ACE2 activities and is prevented by angiotensin-(1-7) or an angiotensin II receptor antagonist. *J Pathol* 2011;225(4): 618–27.
83. Raiden S, Nahmod K, Nahmod V, et al. Nonpeptide antagonists of AT1 receptor for angiotensin II delay the onset of acute respiratory distress syndrome. *J Pharmacol Exp Ther* 2002;303(1):45–51.
84. Wosten-van Asperen RM, Lutter R, Specht PA, et al. Ventilator-induced inflammatory response in lipopolysaccharide-exposed rat lung is mediated by angiotensin-converting enzyme. *Am J Pathol* 2010;176(5):2219–27.
85. Kuba K, Imai Y, Rao S, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. *Nat Med* 2005;11(8):875–9.
86. Imai Y, Kuba K, Rao S, et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. *Nature* 2005;436(7047):112–6.

87. Trembl B, Neu N, Kleinsasser A, et al. Recombinant angiotensin-converting enzyme 2 improves pulmonary blood flow and oxygenation in lipopolysaccharide-induced lung injury in piglets. *Crit Care Med* 2010;38(2):596–601.
88. Haschke M, Schuster M, Poglitsch M, et al. Pharmacokinetics and pharmacodynamics of recombinant human angiotensin-converting enzyme 2 in healthy human subjects. *Clin Pharmacokinet* 2013;52(9):783–92.
89. Cao W, Jin L, Zhou Z, et al. Overexpression of intrarenal renin-angiotensin system in human acute tubular necrosis. *Kidney Blood Press Res* 2016;41(6):746–56.
90. Alge JL, Karakala N, Neely BA, et al. Urinary angiotensinogen and risk of severe AKI. *Clin J Am Soc Nephrol* 2013;8(2):184–93.
91. Lankadeva YR, Kosaka J, Evans RG, et al. Urinary oxygenation as a surrogate measure of medullary oxygenation during angiotensin II therapy in septic acute kidney injury. *Crit Care Med* 2018;46(1):e41–8.
92. Efrati S, Berman S, Hamad RA, et al. Effect of captopril treatment on recuperation from ischemia/reperfusion-induced acute renal injury. *Nephrol Dial Transplant* 2012;27(1):136–45.
93. Zhang J, Rudemiller NP, Patel MB, et al. Competing actions of type 1 angiotensin II receptors expressed on T lymphocytes and kidney epithelium during cisplatin-induced AKI. *J Am Soc Nephrol* 2016;27(8):2257–64.
94. Fang F, Liu GC, Zhou X, et al. Loss of ACE2 exacerbates murine renal ischemia-reperfusion injury. *PLoS One* 2013;8(8):e71433.